CGON (CG Oncology) Insider Ownership : 0.86 % (As of Apr. 14, 2025)

View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, CG Oncology's insider ownership is 0.86%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, CG Oncology's Institutional Ownership is 87.28%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, CG Oncology's Float Percentage Of Total Shares Outstanding is 99.14%.

CG Oncology Insider Ownership Historical Data

The historical data trend for CG Oncology's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Insider Ownership Chart

CG Oncology Historical Data

The historical data trend for CG Oncology can be seen below:

	2024-06-30	2024-07-31	2024-08-31	2024-09-30	2024-10-31	2024-11-30	2024-12-31	2025-01-31	2025-02-28	2025-03-31
Insider Ownership	0.98	0.98	0.97	0.97	0.97	0.97	0.86	0.86	0.86	0.86

CG Oncology Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.

CG Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Insider Ownership

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618

Website

https://www.cgoncology.com

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.